Moderna (MRNA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Moderna (MRNA) is Moderate Outperform.

The composite score behind that read is +0.21, weighing +0.38 of bullish evidence against -0.27 bearish.

Moderna last closed at $225.00, +14.21% on the session.

Against the IVW growth benchmark the position is +13.41% over the forecast window.

The read is built from 15 underlying insights — 8 bullish and 7 bearish.

Agreement across those insights is 53%.

3 graded predictions for MRNA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Moderna in the 21st percentile on return on equity, where 100 is best.

Moderna is classified under Health Care / Biotechnology, with a market capitalisation of $78.65B.

StockMap tracks Moderna as the 5th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Moderna ranks 11th of 381 in the group, against a group median of -0.08.